Theratechnologies Inc. (THTX)

NASDAQ: THTX · IEX Real-Time Price · USD
0.820
0.00 (0.01%)
At close: Mar 24, 2023, 3:10 PM
0.861
+0.041 (5.00%)
After-hours: Mar 24, 2023, 5:39 PM EDT
0.01%
Market Cap 79.39M
Revenue (ttm) 60.19M
Net Income (ttm) -35.52M
Shares Out 96.81M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE 55.87
Dividend n/a
Ex-Dividend Date n/a
Volume 27,043
Open 0.890
Previous Close 0.820
Day's Range 0.772 - 0.890
52-Week Range 0.700 - 2.770
Beta 1.58
Analysts Buy
Price Target 3.71 (+352.38%)
Earnings Date Apr 12, 2023

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystr... [Read more]

Sector Healthcare
Founded 1993
Employees 87
Stock Exchange NASDAQ
Ticker Symbol THTX
Full Company Profile

Financial Performance

In 2022, THTX's revenue was 80.06 million, an increase of 14.66% compared to the previous year's 69.82 million. Losses were -47.24 million, 48.9% more than in 2021.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for THTX stock is "Buy." The 12-month stock price forecast is $3.71, which is an increase of 352.38% from the latest price.

Price Target
$3.71
(352.38% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

MONTREAL, March 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

1 week ago - GlobeNewsWire

Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price

MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

2 weeks ago - GlobeNewsWire

Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022

MONTREAL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

3 weeks ago - GlobeNewsWire

Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management

Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche

3 weeks ago - GlobeNewsWire

Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV

MONTREAL, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

1 month ago - GlobeNewsWire

Theratechnologies Announces Path to Resume TH1902 Clinical Development

MONTREAL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

1 month ago - GlobeNewsWire

Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

MONTREAL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innov...

1 month ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theratechnologies Inc. - THTX

New York, New York--(Newsfile Corp. - January 7, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX). S...

2 months ago - Newsfile Corp

Open Letter to Shareholders from CEO Paul Levesque

Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan's Key Objectives Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan's Key Objectives

2 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX)....

3 months ago - Newsfile Corp

Theratechnologies Announces Update from Ongoing TH1902 Study

This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 202...

4 months ago - GlobeNewsWire

Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays

MONTREAL, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

5 months ago - GlobeNewsWire

Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update

- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million

5 months ago - GlobeNewsWire

Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium

MONTREAL, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

5 months ago - GlobeNewsWire

Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population

MONTREAL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

6 months ago - GlobeNewsWire

Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update

MONTREAL, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innova...

6 months ago - GlobeNewsWire

Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference

MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

6 months ago - GlobeNewsWire

Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth

MONTREAL, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

6 months ago - GlobeNewsWire

Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference

MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

8 months ago - GlobeNewsWire

Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens

MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

8 months ago - GlobeNewsWire

Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement

This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 202...

8 months ago - GlobeNewsWire

Theratechnologies Stock Jumps After Q2 Earnings, FY22 Guidance

Theratechnologies Inc (NASDAQ: THTX) issued an update on the dose escalation portion of the TH1902 Phase 1 safety study.  18 heavily pretreated patients were enrolled.

9 months ago - Benzinga

Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update

– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million

9 months ago - GlobeNewsWire

Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies

MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commerciali...

9 months ago - GlobeNewsWire

Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management

Financing Will Significantly Strengthen the Balance Sheet and Extend Cash Runway

9 months ago - GlobeNewsWire